A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
City of Hope Medical Center
Seagen Inc.
Novartis
City of Hope Medical Center
Tempus AI
Revolution Medicines, Inc.